Teva Launches Generic Seroquel on First Day of Patent Loss (TEVA, AZN)

Health and Healthcare

Published: March 26, 2012 2:29 pm

Last Updated: March 26, 2020 7:24 pm

We noted earlier today that AstraZeneca plc (NYSE: AZN) had lost a patent ruling and that the company’s anti-pyschotic drug Seroquel lost its patent protection today. That’s all it took for Teva Pharmaceuticals Industries Ltd. (NASDAQ: TEVA) to kick out its quetiapine generic for Seroquel.

Teva’s price sheet shows the difference a patent makes in the UK. An equal supply of 100-mg coated tablets of Seroquel costs about $180 compared with the generic cost of about $27. In its announcement, Teva notes that it has released 10 new products in 11 weeks, and 7 of those came on the first day of patent expiration.

Teva’s announcement is available here.

The company’s share price is up about 1.5% at $43.72 in a 52-week range of $35.00-$51.30.

It’s Your Money, Your Future—Own It (sponsor)

Retirement can be daunting, but it doesn’t need to be.

Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!

Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.